170 related articles for article (PubMed ID: 19687322)
21. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
Bengala C; Zamagni C; Pedrazzoli P; Matteucci P; Ballestrero A; Da Prada G; Martino M; Rosti G; Danova M; Bregni M; Jovic G; Guarneri V; Maur M; Conte PF;
Br J Cancer; 2006 Apr; 94(7):1016-20. PubMed ID: 16570045
[TBL] [Abstract][Full Text] [Related]
22. Brain metastases in patients receiving trastuzumab for breast cancer.
Errante D; Bernardi D; Bianco A; Salvagno L
Neurol Sci; 2007 Mar; 28(1):52-3. PubMed ID: 17385098
[No Abstract] [Full Text] [Related]
23. Trastuzumab and breast cancer.
Palmieri C; Powles T; Vigushin D
N Engl J Med; 2001 Sep; 345(13):996-7. PubMed ID: 11575297
[No Abstract] [Full Text] [Related]
24. Herceptin and the heart--a molecular modifier of cardiac failure.
Chien KR
N Engl J Med; 2006 Feb; 354(8):789-90. PubMed ID: 16495390
[No Abstract] [Full Text] [Related]
25. [Difficulties in echocardiographic monitoring of trastuzumab therapy in breast cancer patients: case report and review of recommendations].
Duchnowska R; Szmit S; Szczylik C; Opolski G
Kardiol Pol; 2008 Aug; 66(8):895-8. PubMed ID: 18803144
[No Abstract] [Full Text] [Related]
26. Trastuzumab for early breast cancer: current status and future directions.
Dinh P; de Azambuja E; Piccart-Gebhart MJ
Clin Adv Hematol Oncol; 2007 Sep; 5(9):707-17. PubMed ID: 17982412
[TBL] [Abstract][Full Text] [Related]
27. Tomorrow's targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity?
Magné N; Chargari C; MacDermed D; Conforti R; Védrine L; Spano JP; Khayat D
Crit Rev Oncol Hematol; 2010 Dec; 76(3):186-95. PubMed ID: 20138541
[TBL] [Abstract][Full Text] [Related]
28. [Clinical implications of trastuzumab].
Saeki T; Takashima S
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263
[TBL] [Abstract][Full Text] [Related]
29. Clinical cardiac tolerability of trastuzumab.
Perez EA; Rodeheffer R
J Clin Oncol; 2004 Jan; 22(2):322-9. PubMed ID: 14722042
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
31. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
Gianni L; Salvatorelli E; Minotti G
Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
[TBL] [Abstract][Full Text] [Related]
32. [Trastuzumab-associated cardiac dysfunction].
Okada Y; Kanbayashi C; Sato N
Gan To Kagaku Ryoho; 2010 Apr; 37(4):665-9. PubMed ID: 20414023
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Rowan K
J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
[No Abstract] [Full Text] [Related]
34. Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
Popat S; Smith IE
Nat Clin Pract Oncol; 2008 Jun; 5(6):324-35. PubMed ID: 18364726
[TBL] [Abstract][Full Text] [Related]
35. Heart of darkness: the downside of trastuzumab.
Hayes DF; Picard MH
J Clin Oncol; 2006 Sep; 24(25):4056-8. PubMed ID: 16908930
[No Abstract] [Full Text] [Related]
36. Trastuzumab-induced cardiotoxicity.
Moss LS; Starbuck MF; Mayer DK; Harwood EB; Glotzer J
Oncol Nurs Forum; 2009 Nov; 36(6):676-85. PubMed ID: 19887355
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
[TBL] [Abstract][Full Text] [Related]
39. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
Fiúza M
Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
[TBL] [Abstract][Full Text] [Related]
40. Continuing trastuzumab beyond progression.
Jahanzeb M
J Clin Oncol; 2009 Apr; 27(12):1935-7. PubMed ID: 19289613
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
